Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment.
10.1016/j.apsb.2024.10.014
- Author:
Lauren C NAATZ
1
;
Shuyun DONG
1
;
Brian EVAVOLD
2
;
Xiangyang YE
3
;
Mingnan CHEN
1
Author Information
1. Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
2. Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
3. Department of Pharmacotherapy, University of Utah, Salt Lake City, UT 84112, USA.
- Publication Type:Journal Article
- Keywords:
Antibody-dependent cellular cytotoxicity;
Autoimmune disease;
Bispecific antibody;
Bispecific killer engager;
Immunotherapy;
Natural killer cell;
PD-1;
PD-1-positive cells
- From:
Acta Pharmaceutica Sinica B
2025;15(3):1230-1241
- CountryChina
- Language:English
-
Abstract:
Bispecific killer cell engagers (BiKEs) are a powerful tool to incite the killing power of natural killer (NK) cells. Here, we posited that the BiKE technology could be utilized to deplete activated immune cells expressing programmed death-1 (PD-1+ cells), and hence treat autoimmune diseases since these cells drive the disorders. We designed and generated PD-1 BiKE that targets an activating NK cell receptor, CD16, and PD-1. PD-1 BiKE showed specific binding to PD-1+ cells and engaged CD16 simultaneously. PD-1 BiKE enhanced NK cell-mediated apoptosis and depletion of PD-1+ Raji cells, but not PD-1- Raji cells. Further, PD-1 BiKE induced apoptosis of primary PD-1+ T lymphocytes that are highly relevant to autoimmune disease progression. The BiKE depleted 42% of primary T cells that were stimulated in vitro. Importantly, those ablated primary T cells were activated cells. Meanwhile, naive T cells were spared by the BiKE treatment, supporting the crucial selectivity of PD-1 BiKE-directed cell depletion. Lastly, PD-1 BiKE is more effective than a conventional depleting antibody in the depletion of PD-1+ cells. The current work supports PD-1 BiKE is a selective, potent, and safe tool to deplete PD-1+ cells.
